Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy

NCT04398524 is registered in ClinicalTrials.gov with ISA Pharmaceuticals as lead sponsor.

NCT NCT04398524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04398524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy
Lead sponsor
ISA Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2021
Completion date
December 30, 2024
Enrollment
65 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the oropharynx